carmustine has been researched along with Necrosis in 21 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The outcome after treatment for glioblastoma remains poor." | 6.69 | Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. ( Altavilla, G; Brandes, AA; Carollo, C; Chierichetti, F; Ermani, M; Florentino, MV; Rigon, A; Turazzi, S; Zampieri, P, 1998) |
| "During follow-up, local disease progression was observed in 27 patients, and 23 of them died." | 5.35 | Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. ( Albright, RE; Breneman, JC; Darakchiev, BJ; Warnick, RE, 2008) |
| " Here we examine the extent of β-GUS release in small C6 glioma tumors after a single treatment of doxorubicin (DOX), carmustine (BCNU) and tumor necrosis factor α (TNF-α) with positron emission tomography (PET) and the tracer 1-O-(4-(2-fluoroethyl-carbamoyloxymethyl)-2-nitrophenyl)-O-β-d-glucopyronuronate, [(18)F]FEAnGA, which has been proven to be selective for extracellular β-GUS." | 3.78 | Induction of β-glucuronidase release by cytostatic agents in small tumors. ( Antunes, IF; de Vries, EF; Di Gialleonardo, V; Dierckx, RA; Elsinga, PH; Haisma, HJ; van Waarde, A; Willemsen, AT, 2012) |
| "Diquat administration produces hepatic necrosis in male Fischer-344 rats, and minimally in male Sprague-Dawley rats, with massive oxidant stress observable in both strains as evidenced by increased biliary efflux of glutathione disulfide (GSSG)." | 3.67 | Effect of BCNU pretreatment on diquat-induced oxidant stress and hepatotoxicity. ( Smith, CV, 1987) |
| "Carmustine 80 mg/m(2) was given during RT, then every 8 weeks for 6 cycles." | 2.74 | Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. ( Curran, WJ; Diaz, A; Gilbert, MR; Kresel, JJ; Mehta, MP; Michalski, JM; Moughan, J; Purdy, J; Simpson, J; Tsien, C, 2009) |
| "The outcome after treatment for glioblastoma remains poor." | 2.69 | Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. ( Altavilla, G; Brandes, AA; Carollo, C; Chierichetti, F; Ermani, M; Florentino, MV; Rigon, A; Turazzi, S; Zampieri, P, 1998) |
| "Radiation necrosis impacts the quality of life in cancer survivors, and it is essential to detect and effectively treat this entity as early as possible." | 2.49 | Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations. ( Marko, NF; Rahmathulla, G; Weil, RJ, 2013) |
| "During follow-up, local disease progression was observed in 27 patients, and 23 of them died." | 1.35 | Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. ( Albright, RE; Breneman, JC; Darakchiev, BJ; Warnick, RE, 2008) |
| " With local delivery of O6BG, the MTD of BCNU in combination with O6BG was increased." | 1.31 | Toxicity of intracranial and intraperitoneal O6-benzyl guanine in combination with BCNU delivered locally in a mouse model. ( Biser-Rohrbaugh, A; Bunton, TE; Carson, BS; Gabikian, P; Guarnieri, M; Tyler, BM; Weingart, J; Wu, QZ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (52.38) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rahmathulla, G | 1 |
| Marko, NF | 1 |
| Weil, RJ | 1 |
| Tsien, C | 1 |
| Moughan, J | 1 |
| Michalski, JM | 1 |
| Gilbert, MR | 1 |
| Purdy, J | 1 |
| Simpson, J | 1 |
| Kresel, JJ | 1 |
| Curran, WJ | 1 |
| Diaz, A | 1 |
| Mehta, MP | 1 |
| Rusthoven, KE | 1 |
| Olsen, C | 1 |
| Franklin, W | 1 |
| Kleinschmidt-DeMasters, BK | 2 |
| Kavanagh, BD | 1 |
| Gaspar, LE | 1 |
| Lillehei, K | 1 |
| Waziri, A | 1 |
| Damek, DM | 1 |
| Chen, C | 1 |
| Antunes, IF | 1 |
| Haisma, HJ | 1 |
| Elsinga, PH | 1 |
| Di Gialleonardo, V | 1 |
| van Waarde, A | 1 |
| Willemsen, AT | 1 |
| Dierckx, RA | 1 |
| de Vries, EF | 1 |
| Guarnieri, M | 1 |
| Biser-Rohrbaugh, A | 1 |
| Tyler, BM | 1 |
| Gabikian, P | 1 |
| Bunton, TE | 1 |
| Wu, QZ | 1 |
| Weingart, J | 1 |
| Carson, BS | 1 |
| Darakchiev, BJ | 1 |
| Albright, RE | 1 |
| Breneman, JC | 1 |
| Warnick, RE | 1 |
| Moore, JV | 1 |
| Kokunai, T | 1 |
| Kuwamura, K | 1 |
| Brandes, AA | 1 |
| Rigon, A | 1 |
| Zampieri, P | 1 |
| Ermani, M | 1 |
| Carollo, C | 1 |
| Altavilla, G | 1 |
| Turazzi, S | 1 |
| Chierichetti, F | 1 |
| Florentino, MV | 1 |
| Antunes, F | 1 |
| Cadenas, E | 1 |
| Mahaley, MS | 1 |
| Vogel, FS | 1 |
| Burger, P | 1 |
| Ghatak, NR | 1 |
| Tonn, JC | 1 |
| Roosen, K | 1 |
| Schachenmayr, W | 1 |
| Nagahiro, S | 1 |
| Yamamoto, YL | 1 |
| Diksic, M | 1 |
| Mitsuka, S | 1 |
| Sugimoto, S | 1 |
| Feindel, W | 1 |
| Rosenblum, MK | 1 |
| Delattre, JY | 1 |
| Walker, RW | 1 |
| Shapiro, WR | 1 |
| Di Chiro, G | 1 |
| Oldfield, E | 1 |
| Wright, DC | 1 |
| De Michele, D | 1 |
| Katz, DA | 1 |
| Patronas, NJ | 1 |
| Doppman, JL | 1 |
| Larson, SM | 1 |
| Ito, M | 1 |
| Kufta, CV | 1 |
| Steen, RG | 1 |
| Tamargo, RJ | 1 |
| McGovern, KA | 1 |
| Rajan, SS | 1 |
| Brem, H | 1 |
| Wehrle, JP | 1 |
| Glickson, JD | 1 |
| Sijens, PE | 1 |
| Bovee, WM | 1 |
| Smith, CV | 1 |
| Théron, J | 1 |
| Villemure, JG | 1 |
| Worthington, C | 1 |
| Tyler, JL | 1 |
| Loth, TS | 1 |
| Eversmann, WW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme[NCT00003417] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 1998-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for carmustine and Necrosis
| Article | Year |
|---|---|
Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations.
Topics: Anticoagulants; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brachytherapy; Brain Neoplas | 2013 |
2 trials available for carmustine and Necrosis
| Article | Year |
|---|---|
Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Carmustine; Combined Modality Therapy; Drug A | 2009 |
Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1998 |
18 other studies available for carmustine and Necrosis
| Article | Year |
|---|---|
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Induction of β-glucuronidase release by cytostatic agents in small tumors.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2012 |
Toxicity of intracranial and intraperitoneal O6-benzyl guanine in combination with BCNU delivered locally in a mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carmustine; Dose-Resp | 2002 |
Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain; Brain Neoplasms; Carmust | 2008 |
Death of intestinal crypts and of their constituent cells after treatment by chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Survival; Cyclophosphamide; Dactinomycin; Doxorubic | 1984 |
Effect of perfluorochemicals on BCNU chemotherapy: preliminary study in a rat brain tumor model.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Drug Combinations; Drug Therapy, Combination; Fluorocar | 1982 |
Cellular titration of apoptosis with steady state concentrations of H(2)O(2): submicromolar levels of H(2)O(2) induce apoptosis through Fenton chemistry independent of the cellular thiol state.
Topics: 2,2'-Dipyridyl; Apoptosis; Carmustine; Chelating Agents; Deferoxamine; Diamide; Enzyme Inhibitors; F | 2001 |
Neuropathology of tissues from patients treated by the Brain Tumor Study Group.
Topics: Adult; Anaplasia; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Necrosis; Radiation Inj | 1977 |
Brain necroses after intraarterial chemotherapy and irradiation of malignant gliomas--a complication of both ACNU and BCNU?
Topics: Brain; Brain Diseases; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therap | 1991 |
Neurotoxicity after intracarotid 1,3-bis(2-chloroethyl)-1-nitrosourea administration in the rat: hemodynamic changes studied by double-tracer autoradiography.
Topics: Aminobutyrates; Amygdala; Animals; Antipyrine; Autoradiography; Blood-Brain Barrier; Carbon Radioiso | 1991 |
Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans; Infusions, I | 1989 |
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies.
Topics: Adolescent; Adult; Aged; Brain; Brain Neoplasms; Carmustine; Child; Child, Preschool; Deoxyglucose; | 1988 |
In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology.
Topics: Animals; Carmustine; Energy Metabolism; Extracellular Space; Glioma; Magnetic Resonance Spectroscopy | 1988 |
In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology.
Topics: Animals; Brain Neoplasms; Carmustine; Glioma; Humans; Magnetic Resonance Spectroscopy; Necrosis; Rat | 1988 |
Effect of BCNU pretreatment on diquat-induced oxidant stress and hepatotoxicity.
Topics: Animals; Carmustine; Diquat; Glutathione; Glutathione Disulfide; Glutathione Reductase; Lipid Peroxi | 1987 |
Superselective intracerebral chemotherapy of malignant tumours with BCNU. Neuroradiological considerations.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheterization; | 1986 |
Treatment methods for extravasations of chemotherapeutic agents: a comparative study.
Topics: Animals; Antidotes; Antineoplastic Agents; Carmustine; Dactinomycin; Debridement; Disease Models, An | 1986 |
Intracarotid BCNU leukoencephalopathy.
Topics: Astrocytoma; Autopsy; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Humans; Infusion | 1986 |